Market Overview

The Global Next-Generation Sequencing (NGS) Market is Estimated to Witness a CAGR of 18.6% During 2018-2024 -- Emerging Applications & Evolution of Personalized Medicine

Share:

Dublin, Aug. 10, 2018 (GLOBE NEWSWIRE) -- The "Global Next-Generation Sequencing (NGS) Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing market is estimated to witness a CAGR of 18.6% during the forecast period 2018-2024.

Illumina, Pacific Biosciences of California, Thermo Fisher scientific and Oxford Nanopore technology offers next-generation sequencing instruments based on different technologies such as Reversible terminator sequencing, Sequencing by ligation, Single-molecule, real-time sequencing (SMRT), ion semiconductor sequencing technology and Nanopore sequencing technology respectively.

Wide range of diagnostic applications, continuous technology advancements are making it more efficient and user-friendly, but the complications associated with data storage and lack of skilled professional are some of the factors which may hamper growth to an extent.

Segment Analysis

The next-generation sequencing market by technology is segmented into reversible terminator sequencing, ion semiconductor sequencing, sequencing by ligation, single molecule real-time sequencing, nanopore sequencing and others. Reversible terminator sequencing occupied a major market share in 2017 and is expected to remain same during the forecasted period.

The market by product type is segmented into instruments, consumables and reagents and services. The services segment of the NGS market includes data analysis services and sequencing services. Among various application, consumables and reagents occupied the largest share in 2017, due to increased usage and need of consumables throughout the sample preparation, library construction, and various other pre-requisite steps of next-generation sequencing.

The market by application is segmented into diagnostics, biomarker discovery, drug discovery, agriculture and animal research and others. Diagnostics includes prenatal testing, cancer diagnostics, genetic screening, pre-implantation, HLA typing and various other clinical diagnostics applications. The diagnostics application occupied a major share in 2017, due to increasing usage of next-generation sequencing for disease diagnosis.

The market by end-users is segmented into academic and research institutes, hospitals and clinics, biotech and pharma companies and others. Among various end-users of the NGS market, academic and research institutes occupied a major share in 2017.

The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global next-generation sequencing market, followed by Europe. Asia-Pacific region is expected to grow at high CAGR during the forecasted period due to increasing funding for healthcare research, growing patient pool, and increasing healthcare expenditure. The markets in emerging counties such as, India, China and Brazil are expected to grow at a rapid pace for next five years.

Competitive Analysis

Currently the next-generation sequencing market is consolidated with few key companies due to the involvement of complicated technologies and the requirement of high capital investment. Sequencing-based test may soon be regarded as the gold standard in the field of molecular diagnostics. The increase in the applications of NGS has made many biotechnological firms and diagnostic laboratories to invest heavily in this field by launching new products or acquiring other smaller firms or by collaboration.

For instance, in August 2017, US based Illumina and Telegraph Hill Partners launched Verogen, Inc. to drive adoption of NGS in the global forensic genomics Market. In February 2018, Twist Bioscience entered the NGS sample prep market with the launch of its first target enrichment products. In March 2017, MedGenome launched NGS based liquid biopsy blood test Oncotrack for the diagnosis of cancer in India.

Key Topics Covered

1 Industry Outlook
1.1 Market Overview
1.2 Total addressable market

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition
3.2 Advantages of next-generation sequencing
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the next-generation sequencing market
3.5 Related Markets
3.5.1 Polymerase chain reaction (PCR)
3.5.2 In-situ Hybridization
3.5.3 Microarray

4 Market Outlook
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces

5 Market Characteristics
5.1 DRO - Global Next-generation sequencing Market Dynamics
5.1.1 Drivers
5.1.1.1 Usage of sequencing in wide range of diagnostic application
5.1.1.2 High speed, accuracy and reduced sequencing cost
5.1.2 Opportunities
5.1.2.1 Emerging applications of next-generation sequencing
5.1.2.2 Evolution of personalized medicine
5.1.3 Restraints
5.1.3.1 Complications associated with NGS data storage
5.1.3.2 Lack of skilled professional
5.2 DRO - Impact Analysis
5.3 Key Stakeholders

6 Technology: Market Size & Analysis
6.1 Overview
6.2 Reversible terminator sequencing
6.3 Ion semiconductor sequencing
6.4 Sequencing by ligation
6.5 Single molecule real-time (SMRT) sequencing
6.6 Nanopore sequencing
6.7 Others

7 Product: Market Size & Analysis
7.1 Overview
7.2 Instruments
7.3 Consumables and reagents
7.4 Services

8 Applications: Market Size & Analysis
8.1 Overview
8.2 Diagnostics
8.3 Biomarker discovery
8.4 Drug discovery
8.5 Agriculture and animal research
8.6 Other application

9 End-User: Market Size & Analysis
9.1 Overview
9.2 Hospital and reference laboratories
9.3 Academic and research institutions
9.4 Biotech and pharma companies
9.5 Others

10 Regions: Market Size and Analysis
10.1 Overview
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World

11 Competitive Landscape
11.1 Overview

12 Vendor Profiles
12.1 Illumina, Inc.
12.1.1 Overview
12.1.2 Illumina, Inc.: Recent Developments
12.1.3 Business Units
12.1.4 Geographic Revenue
12.1.5 Business Focus
12.1.6 SWOT Analysis
12.1.7 Business Strategies
12.2 Thermo Fisher Scientific Inc.
12.2.1 Overview
12.2.2 Thermo Fisher Scientific Inc.: Recent Developments
12.2.3 Business Units
12.2.4 Geographic Presence
12.2.5 Business Focus
12.2.6 SWOT Analysis
12.2.7 Business Strategies
12.3 Pacific Biosciences of California, Inc.
12.3.1 Overview
12.3.2 Geographic Presence
12.3.3 Business Focus
12.3.4 SWOT Analysis
12.3.5 Business Strategies
12.4 Oxford Nanopore Technologies Ltd
12.4.1 Overview
12.4.2 Business Focus
12.4.3 SWOT Analysis
12.4.4 Business Strategies
12.5 Beijing Genomics Institute
12.5.1 Overview
12.5.2 Business Focus
12.5.3 SWOT Analysis
12.5.4 Business Strategies

13 Companies to Watch for
13.1 DNASTAR, Inc.
13.1.1 Overview
13.2 Agilent Technologies, Inc.
13.2.1 Overview
13.3 Qiagen N.V.
13.3.1 Overview
13.4 Eurofins Scientific
13.4.1 Overview
13.5 Biomatters Limited
13.5.1 Overview
13.6 F. Hoffmann-La Roche
13.6.1 Overview

For more information about this report visit https://www.researchandmarkets.com/research/jdl4s2/the_global?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Molecular Diagnostics 

Primary Logo

View Comments and Join the Discussion!